Nicholas von Guionneau is a Senior Analyst at Catalio Capital Management, where he is responsible for making venture and private credit investments in breakthrough biomedical technology companies. Nicholas represents Catalio on the Board of Proto Axiom and as a Board Observer at Boost Neuroscience, Character Biosciences, LifeSprout Bio, Orasis Pharmaceuticals, Roshal Health and SetPoint Medical.
Prior to Catalio, Nicholas was a Postdoctoral Fellow at Johns Hopkins Medicine. His research was in the field of peripheral nerve regeneration and focused on pre-clinical development of small protein drug delivery systems, neurotherapeutics and implantable neurodevices. Before moving into research, he was a clinical doctor at Guy’s and St. Thomas’ NHS Trust in London, UK.
Nicholas earned his MBBS (Bachelor of Medicine, Bachelor of Surgery) degree at Imperial College School of Medicine in London, and his BSc in Medical Sciences (Surgery and Anaesthesia), also from Imperial College London.
